Vaxart Announces Third Quarter 2019 Financial Results and Provides Corporate Update


You May Also Like

Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017

Positive CHMP Opinion for Lutetium Lu 177 Dotatate* (Lutathera®) for GEP-NETS FDA Acknowledged Receipt ...

EyeGate Pharmaceuticals Reports Full-year 2016 Financial Results and Provides Business Update

WALTHAM, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or ...